• XAV-939 in Bone Metabolism: Beyond Wnt Inhibition to Metabol

  2026-05-27

  Discover how XAV-939, a potent tankyrase inhibitor, uniquely modulates bone formation by influencing Wnt/β-catenin signaling and metabolic pathways. This in-depth article extends current knowledge with new insights for osteogenic differentiation and disease modeling.

• Reversine Protocols: Aurora Kinase Inhibition in Cancer Mode

  2026-05-27

  Reversine is a potent Aurora kinase inhibitor designed for dissecting mitotic regulation and cell cycle control in cancer biology research. It is best suited for in vitro and in vivo studies on Aurora kinase signaling, particularly in cancer cell proliferation and apoptosis workflows. This reagent is for research use only and is not appropriate for diagnostic or medical applications.

• Estradiol in Research: Protocols, Applications, and Troubles

  2026-05-26

  Estradiol (17 beta-estradiol) is indispensable for modeling estrogen receptor signaling and autophagy-driven organ protection, especially in cardiovascular and metabolic disease research. This article delivers workflow enhancements, practical troubleshooting, and evidence-based guidance to maximize experimental reproducibility with APExBIO's Estradiol.

• Simvastatin (Zocor): Applied Workflows in Lipid & Cancer Res

  2026-05-26

  Simvastatin (Zocor) delivers unmatched utility for dissecting cholesterol metabolism and apoptosis induction in hepatic cancer models. This guide provides actionable protocol enhancements, advanced troubleshooting, and key insights from machine learning-driven phenotypic profiling, making it indispensable for bench scientists seeking reproducible, data-rich outcomes.

• NU7441 (KU-57788): Precision DNA-PK Inhibition in Oncology R

  2026-05-25

  NU7441 (KU-57788) stands out as a highly selective DNA-PK inhibitor, enabling robust DNA repair and oncology research workflows. Its nanomolar potency and ATP-competitive mechanism unlock new experimental possibilities in cell cycle analysis and chemosensitization studies, offering advanced troubleshooting and optimization options for translational scientists.

• Evaluating Acid Reducer Interactions with Ribociclib Succina

  2026-05-25

  This study rigorously investigates whether acid-reducing agents, such as proton pump inhibitors, impact the solubility and absorption of ribociclib succinate—a key CDK4/6 inhibitor in breast cancer research. By applying a Quality by Design (QbD) analytical approach, the authors demonstrate that clinically relevant pH shifts do not significantly affect ribociclib's bioavailability, clarifying a persistent question in combination therapy protocols.

• Roscovitine (Seliciclib): Precision Tools for Cancer Cell Cy

  2026-05-24

  Roscovitine (Seliciclib) empowers researchers to induce cell cycle arrest in late prophase with unparalleled selectivity, enabling precise dissection of cyclin-dependent kinase signaling in cancer biology. This guide delivers actionable workflows, troubleshooting tactics, and insights into the compound’s translation from bench to advanced tumor models.

• DGLA-Induced Ferroptosis via ACSL4 in AML: Mechanisms and Im

  2026-05-23

  The reference study demonstrates that exogenous dihomo-γ-linolenic acid (DGLA) induces ferroptosis in acute myeloid leukemia (AML) cells through ACSL4-mediated lipid metabolic reprogramming. These findings highlight a novel therapeutic avenue for overcoming chemoresistance in AML by exploiting ferroptosis, with implications for metabolic targeting in cancer research.

• KU-55933: ATM Kinase Inhibitor for Advanced DNA Damage Respo

  2026-05-22

  KU-55933 unlocks precise control of ATM signaling, enabling high-fidelity DNA damage response and cancer cell cycle studies. This guide delivers actionable workflows, troubleshooting strategies, and translates the latest nuclear cGAS findings for advanced assay design.

• Protease Inhibitor Cocktail: Elevating Plant Protein Stabili

  2026-05-22

  Unlock high-fidelity plant protein workflows with the EDTA-free Protease Inhibitor Cocktail, engineered for maximal stability and reproducibility in demanding extract preparations. APExBIO’s advanced formulation enables robust, reproducible Western blotting and immunoassays, transforming the reliability of plant molecular research.

• Cyclo (-RGDfC) in Cell-Based Assays: Reliable αvβ3 Integrin

  2026-05-21

  Cyclo (-RGDfC) (SKU A8790) offers high-affinity, reproducible αvβ3 integrin targeting for cancer research, particularly in cell viability and migration assays. This article addresses real-world laboratory challenges and provides scenario-driven guidance on protocol optimization, data interpretation, and product selection, emphasizing the peptide’s validated stability and specificity.

• Cyclopamine in Translational Oncology: APOC1-Driven Targets

  2026-05-21

  Explore how Cyclopamine, a leading Hedgehog signaling inhibitor, is transforming targeted cancer research with new insights from APOC1-driven thyroid carcinoma studies. This article uniquely connects molecular mechanism, advanced protocols, and translational applications.

• Eltanexor (KPT-8602): Redefining Chemoprevention via XPO1 In

  2026-05-20

  Explore how Eltanexor (KPT-8602) is transforming cancer research as a second-generation XPO1 inhibitor, with unique efficacy in chemoprevention and nuclear export targeting. This article delivers a deep dive into mechanism, assay design, and the latest translational insights.

• (Z)-4-Hydroxytamoxifen: Deep Dive into ER Modulation & Assay

  2026-05-20

  (Z)-4-Hydroxytamoxifen is a highly potent estrogen receptor modulator, central to advanced endocrine signaling research. This article uniquely explores its biophysical action, assay optimization, and strategic implications for robust estrogen-dependent breast cancer studies.

• Host CK2α–VP2 Interaction Drives CIAV Replication and Pathog

  2026-05-19

  This study reveals that chicken infectious anemia virus (CIAV) directly exploits host CK2α via a specific interaction with its VP2 protein, enabling efficient viral replication and pathogenesis. Disruption of this interaction—either by mutating VP2 or inhibiting CK2α—suppresses viral replication, establishing the VP2–CK2α axis as a promising antiviral target.

405 records 7/27 page Previous Next First page 上5页 678910 下5页 Last page